General Dermatology

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the urgent need for sustainability in dermatology, addressing its environmental impact and advocating for eco-friendly practices in health care.

A new study reveals the effectiveness of two isotretinoin doses for treating recalcitrant facial flat warts, enhancing quality of life and reducing anxiety.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology Times is looking back on the top stories in dermatology from the month of April.

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

This review of the latest dermatologic studies includes insights into the environmental impact of dermatology, submicrobial dosing of antibiotics in dermatology, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology Times is recapping our exclusive expert interviews from the month of April.

The innovative 21-item Hair & Scalp CARE questionnaire is designed to evaluate the psychological impact of hair and scalp conditions on quality of life.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Learn more about the in-depth topics covered in the April 2025 print issue of Dermatology Times.

Explore the top headlines of the week including insights on the latest clinical trials, therapeutic updates, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about the future of regenerative aesthetics, biologic therapies for bullous pemphigoid, phase 3 trial results for Qtorin 3.9% rapamycin gel, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

Complete remission was achieved in over 87% of dupilumab users and 64% of omalizumab users.

This review of the latest dermatologic studies includes insights into epidermolysis bullosa for primary care providers, patient-reported impact of atopic dermatitis on pediatric and adolescent patients, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Palvella has secured its 5th US patent for Qtorin rapamycin, extending intellectual property coverage to 2038 and advancing treatment for microcystic lymphatic malformations.